The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, ...

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48.

In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn's disease 1,2< ...

Significantly, from the pooled GALAXI 2 and 3 study results, guselkumab also demonstrated greater efficacy compared to ustekinumab in endoscopic response and endoscopic remission e at Week 48. 3 ...